Cg-bm1

Preclinical

GGuangZhou Cellgenes Biotechnology Co., Ltd.

Cg-bm1 is one of 12 therapeutic programs targeting Sarcopenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SarcopeniaRecruiting

SarcopeniaPreclinical

Recruiting

Competition

Competitive Landscape

13 competitors in Sarcopenia

#DrugCompanyPhaseTrials

Calciferol

Andriol

Evrenzo

1 4

Deca-Durabolin

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 5

TJ0113

HHangzhou PhecdaMed Co., Ltd.

Phase 2

1 6

Nexavar

Cialis

Gnrh Agonist

1 9

Antibiotics

MMelinta Therapeutics, Inc.

Preclinical

1 10

Testosterone Supplementation

PParacelsus Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Sarcopenia

NCT07865676

PreclinicalRecruiting

Ischemic Stroke

NCT07896941

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

A Clinical Trial to Evaluate the Safety and Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cell (CG-BM1) Injection in the Treatment of Ischemic Stroke

Recruiting·GGuangZhou Cellgenes Biotechnology Co., Ltd.·Preclinical·NCT07896941·87 enrolled

Acute Respiratory Distress Syndrome (ARDS)1 trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cell (CG-BM1) Injection in the Treatment of Moderate-to-Severe Acute Respiratory Distress Syndrome in Adults

Completed·GGuangZhou Cellgenes Biotechnology Co., Ltd.·Phase 1·NCT07892950·15 enrolled

Sarcopenia1 trial

An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia

Recruiting·GGuangZhou Cellgenes Biotechnology Co., Ltd.·Preclinical·NCT07865676·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cg-bm1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cg-bm1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GuangZhou Cellgenes Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GGuangZhou Cellgenes Biotechnology Co., Ltd.

Cg-bm1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Ischemic stroke1 trial

Acute Respiratory Distress Syndrome (ARDS)1 trial

Sarcopenia1 trial

References

Drug Info

Quick Facts

Related News